Failure of combination abacavir + tenofovir + lamivudine (3TC).In late July 2003 GlaxoSmithKline warned physicians that a three-drug combination of lamivudine lamivudine /la·miv·u·dine/ (lah-miv´u-den) a nucleoside analogue that inhibits reverse transcriptase, used as an antiviral agent in the treatment of chronic hepatitis B and, in combination with zidovudine, the treatment of HIV infection and AIDS. la·miv·u·dine (Epivir[R]), abacavir abacavir /abac·a·vir/ (ah-bak´ah-vir) a nonnucleoside reverse transcriptase inhibitor used as the sulfate salt as an antiretroviral antiretroviral /an·ti·ret·ro·vi·ral/ (-ret´ro-vi?ral) effective against retroviruses, or an agent with this quality. an·ti·ret·ro·vi·ral (  n in the treatment of human immunodeficiency virus infection. (Ziagen[R]) and tenofovir tenofovir /te·no·fo·vir/ (te-no´fo-vir?) an antiretroviral agent that inhibits reverse transcriptase; used as t. disoproxil fumarate in the treatment of HIV-1 (human immunodeficiency virus-1) infection. (Viread[TM]) had failed to control HIV effectively in about half the treatment-naive patients in a clinical trial. The cause of the reduced response to this particular regimen 1. A regulated system, as of diet, therapy, or exercise, intended to promote health or achieve another beneficial effect. 2. A course of intense physical training. The company advised: "Abacavir and lamivudine in combination with tenofovir should not be used as a triple antiretroviral therapy when considering a new treatment regimen for naive or pre-treated patients; "Any patient currently controlled on therapy with this combination should be closely monitored and considered for modification of therapy; and "Any usage of this triple combination with other antiretroviral agents should be closely monitored for signs of treatment failure." |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion